United Laboratories International Holdings Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	14yrs

Son yönetim güncellemeleri

Recent updates

CEO

United Laboratories International Holdings CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hoi Shan Tsoi	Executive Chairman	15.6yrs	CN¥4.20m	0.91% HK$ 165.3m
Wing Hon Leung	Vice Chairman	18yrs	CN¥4.17m	0.0086% HK$ 1.6m
Su Yan Zhu	VP & Executive Director	14yrs	CN¥2.52m	0.0034% HK$ 626.3k
Xian Hong Zou	VP & Executive Director	14yrs	CN¥2.52m	0.014% HK$ 2.6m
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	11.4yrs	CN¥2.80m	0.011% HK$ 2.1m
Yu Ping Fang	VP & Executive Director	14yrs	CN¥2.55m	0.0034% HK$ 624.5k
Ming Song	Independent Non-Executive Director	17.5yrs	CN¥234.00k	Veri yok
Peng Oon Chong	Independent Non-Executive Director	15.7yrs	CN¥234.00k	Veri yok
Qiushi Fu	Independent Non-Executive Director	1.4yrs	CN¥118.00k	Veri yok

14.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 3933 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14 yıldır).

United Laboratories International Holdings Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Recent updates

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings released: EPS: CN¥0.82 (vs CN¥0.71 in 1H 2023)

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.54 in FY 2021)

Less than half of directors are independent

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş